Emergent BioSolutions (EBS) Consolidated Net Income (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly Consolidated Net Income of $6.8 million for Q1 2026, down 90.0% year-over-year from $68.0 million in Q1 2025, and up 112.45% quarter-over-quarter from -$54.6 million in Q4 2025.
Emergent BioSolutions (EBS) Consolidated Net Income (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Consolidated Net Income history runs 15 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 90.0% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at -$8.6 million (up 93.47% YoY), while the FY2025 annual figure was $52.6 million, up 127.6% from the prior year.
- Consolidated Net Income for Q1 2026 stood at $6.8 million, up from -$54.6 million in the prior quarter.
- The five-year high for Consolidated Net Income was $114.8 million in Q3 2024, with the low at -$283.1 million in Q2 2024.
- The 5-year median for Consolidated Net Income is -$49.5 million (2023), against an average of -$65.1 million.
- The sharpest annual moves came in 2023 and 2025: Consolidated Net Income sank 4932.43% in 2023, then soared 655.56% in 2025.
- Emergent BioSolutions' Consolidated Net Income stood at -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then slumped by 74.44% to -$54.6 million in 2025, then surged by 112.45% to $6.8 million in 2026.
- Business Quant data shows EBS's Consolidated Net Income at $6.8 million in Q1 2026, -$54.6 million in Q4 2025, and $51.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Emergent BioSolutions | 251.03 Mn | 110.13 Mn | 137.20 Mn | -180.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -180.20 Mn |
| Mar 31, 2026 | 6.80 Mn |
| Dec 31, 2025 | -54.60 Mn |
| Sep 30, 2025 | 51.20 Mn |
| Jun 30, 2025 | -12.00 Mn |
| Mar 31, 2025 | 68.00 Mn |
| Dec 31, 2024 | -31.30 Mn |
| Sep 30, 2024 | 114.80 Mn |
| Jun 30, 2024 | -283.10 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | -49.50 Mn |
| Sep 30, 2023 | -263.40 Mn |
| Jun 30, 2023 | -261.40 Mn |
| Mar 31, 2023 | -186.20 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -87.10 Mn |
| Jun 30, 2022 | -56.40 Mn |
| Mar 31, 2022 | -3.70 Mn |
| Dec 31, 2021 | 177.90 Mn |
| Sep 30, 2021 | -32.70 Mn |